Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Fresenius    FRE   DE0005785604

FRESENIUS

(FRE)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Fresenius : Backs Guidance After Sales, Operating Profit Rose in 1Q

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/02/2019 | 01:31am EDT

By Donato Paolo Mancini

Fresenius SE & Co. KGaA (FRE.XE) on Thursday backed its group guidance after first-quarter sales and operating profit edged higher.

Net income was 465 million euros ($511 million), flat in constant currencies. Operating profit edger higher to EUR1.11 billion, while sales grew 5% to EUR8.52 billion.

The company affirmed its group guidance, despite expected earnings dilution from the acquisition of NxStage.

At Fresenius Medical Care, the company's dialysis division, net profit, operating profit and sales all grew on-year.

Net profit was EUR318 million, operating profit was EUR551 million and sales gained 6% to EUR4.13 billion.

Write to Donato Paolo Mancini at donatopaolo.mancini@dowjones.com; @donatopmancini

Stocks mentioned in the article
ChangeLast1st jan.
FRESENIUS -0.01% 46.13 Delayed Quote.8.85%
FRESENIUS MEDICAL CARE 0.66% 66.7 Delayed Quote.17.76%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on FRESENIUS
06/14FRESENIUS : Medical Care successfully places USD bonds
PU
06/12FRESENIUS SE & CO. KGAA : Release according to Article 40, Section 1 of the WpHG..
EQ
06/11FRESENIUS : Kabi Introduces Neostigmine Methylsulfate Injection, USP Simplist Pr..
AQ
06/06Will Europe's clampdown on faulty medical devices hurt patients?
RE
06/03FRESENIUS SE & CO. KGAA : Release according to Article 40, Section 1 of the WpHG..
EQ
05/31FRESENIUS SE & CO. KGAA : Release according to Article 41 of the WpHG [the Germa..
EQ
05/20FRESENIUS : Ex-dividend day for final dividend
FA
05/17ANNUAL GENERAL MEETING : Fresenius on course for continued growth, 26th straight..
PU
05/16FRESENIUS : Medical Care stays on course for growth – Annual General Meeti..
PU
05/03FRESENIUS SE & CO. KGAA : Notification and public disclosure of transactions by ..
EQ
More news
Financials (€)
Sales 2019 35 249 M
EBIT 2019 4 681 M
Net income 2019 1 884 M
Debt 2019 17 362 M
Yield 2019 1,77%
P/E ratio 2019 13,82
P/E ratio 2020 12,77
EV / Sales 2019 1,22x
EV / Sales 2020 1,12x
Capitalization 25 543 M
Chart FRESENIUS
Duration : Period :
Fresenius Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends FRESENIUS
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 57,3 €
Spread / Average Target 25%
EPS Revisions
Managers
NameTitle
Stephan Sturm President & Chief Executive Officer
Gerd Krick Chairman-Supervisory Board
Rachel Clare Empey Chief Financial Officer
Niko Stumpfögger Deputy Chairman-Supervisory Board
Klaus-Peter Müller Member-Supervisory Board
Sector and Competitors